Chimerix to Participate in Upcoming Investor Conferences
Chimerix (NASDAQ: CMRX), a biopharmaceutical firm, announced its participation in two investor conferences in September. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 1:00 p.m. ET, where Chimerix will present a corporate overview and hold investor meetings. Additionally, management will engage in investor meetings at the Cantor Fitzgerald Virtual Healthcare Conference on September 16. A live audio webcast of the presentation will be available on their Investor Relations website.
Chimerix focuses on developing innovative treatments, including DSTAT for acute lung injury and BCV as a countermeasure for smallpox.
- None.
- None.
DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:
- H.C. Wainwright 22nd Annual Global Investment Conference: Chimerix will present a corporate overview on Monday, September 14 at 1:00 p.m. ET and participate in investor meetings.
- Cantor Fitzgerald Virtual Healthcare Conference: Management will participate in investor meetings on Wednesday, September 16.
A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the US Food and Drug Administration (FDA) and site activation is expected in early 2021. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Media:
David Schull
Russo Partners
858-717-2310
David.Schull@russopartnersllc.com
FAQ
What is Chimerix's stock symbol?
When is Chimerix presenting at the H.C. Wainwright conference?
What are Chimerix's main drug candidates?
When will Chimerix participate in the Cantor Fitzgerald Virtual Healthcare Conference?
Where can I find the audio webcast of Chimerix's conference presentation?
